Nuclear Medicine and Biology
Volume 35, Issue 7 , Pages 783-791 , October 2008

Melanoma affinity in mice and immunosuppressed sheep of [125I]N-(4-dipropylaminobutyl)-4-iodobenzamide, a new targeting agent

  • Pierre Labarre

      Affiliations

    • EA 4231 Université d'Auvergne-INSERM-Centre Jean Perrin, BP 184, 63005 Clermont-Ferrand cedex, France
    • Corresponding Author InformationCorresponding author.
    • ,
  • Janine Papon

      Affiliations

    • EA 4231 Université d'Auvergne-INSERM-Centre Jean Perrin, BP 184, 63005 Clermont-Ferrand cedex, France
    • ,
  • Alison H. Rose

      Affiliations

    • Department of Nuclear Medicine, Fremantle Hospital, Fremantle, WA 6160, Australia
    • ,
  • Jean-Luc Guerquin-Kern

      Affiliations

    • Inserm, U 759, 91405 Orsay, France
    • Institut Curie, Laboratoire Microscopie Ionique, 91405 Orsay, France
    • ,
  • Laurence Morandeau

      Affiliations

    • WA/PET Centre Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia
    • ,
  • Ting-di Wu

      Affiliations

    • Inserm, U 759, 91405 Orsay, France
    • Institut Curie, Laboratoire Microscopie Ionique, 91405 Orsay, France
    • ,
  • Marie-France Moreau

      Affiliations

    • EA 4231 Université d'Auvergne-INSERM-Centre Jean Perrin, BP 184, 63005 Clermont-Ferrand cedex, France
    • ,
  • Martine Bayle

      Affiliations

    • EA 4231 Université d'Auvergne-INSERM-Centre Jean Perrin, BP 184, 63005 Clermont-Ferrand cedex, France
    • ,
  • Jean-Michel Chezal

      Affiliations

    • EA 4231 Université d'Auvergne-INSERM-Centre Jean Perrin, BP 184, 63005 Clermont-Ferrand cedex, France
    • ,
  • Alain Croisy

      Affiliations

    • Inserm, U 759, 91405 Orsay, France
    • Institut Curie, Laboratoire Microscopie Ionique, 91405 Orsay, France
    • ,
  • Jean-Claude Madelmont

      Affiliations

    • EA 4231 Université d'Auvergne-INSERM-Centre Jean Perrin, BP 184, 63005 Clermont-Ferrand cedex, France
    • ,
  • Harvey Turner

      Affiliations

    • Department of Nuclear Medicine, Fremantle Hospital, Fremantle, WA 6160, Australia
    • ,
  • Nicole Moins

      Affiliations

    • EA 4231 Université d'Auvergne-INSERM-Centre Jean Perrin, BP 184, 63005 Clermont-Ferrand cedex, France

Received 16 May 2008 ,Revised 11 July 2008 ,Accepted 13 July 2008.

References 

  1. Devesa SS, Blot W, Stone BJ, Miller BA, Tarone RE, Fraumeni JF. Recent cancer trends in the United States. J Natl Cancer Inst. 1995;87:175–182
  2. Reisfeld RA, Ferrone S. Conference report. International conference on biology of melanoma. Melanoma Res. 1996;6:447–456
  3. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005;365:687–701
  4. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007;17:117–127
  5. Belhocine TZ, Scott AM, Even-Sapir E, Urbain JL, Essner R. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med. 2006;47:957–967
  6. Shöder H, Larson SM, Yeung HWD. PET/CT in oncology: integration into clinical management of lymphoma, melanoma and gastrointestinal malignancies. J Nucl Med. 2004;45:72S–74S
  7. Miao Y, Owen NK, Fisher DR, Hoffman TJ, Quinn T. Therapeutic efficacy of a 188Re-labeled α-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med. 2005;46:121–129
  8. Michelot JM, Moreau MF, Labarre PG, Madelmont JC, Veyre AJ, Papon JM, et al. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J Nucl Med. 1991;32:1573–1580
  9. Michelot JM, Moreau MF, Veyre AJ, Bonafous JF, Bacin FJ, Madelmont JC, et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). J Nucl Med. 1993;34:1260–1266
  10. Moreau MF, Michelot J, Papon J, Bayle M, Labarre P, Madelmont JC, et al. Synthesis, radiolabeling and preliminary evaluation in mice of some N-(diethylaminoethyl)-4-iodobenzamides derivatives as melanoma imaging agents in mice bearing melanoma. Nucl Med Biol. 1995;22:737–747
  11. Brandau W, Niehoff T, Pulawski P, Jonas M, Dutschka K, Sciuk J, et al. Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma. J Nucl Med. 1996;37:1865–1871
  12. Nicholl C, Mohammed A, Hull WE, Bubeck B, Eisenhut M. Pharmacokinetics of iodine-123-IMBA for melanoma imaging. J Nucl Med. 1997;38:127–133
  13. Moreau MF, Labarre P, Foucaud A, Seguin H, Bayle M, Papon J, et al. Radiosynthesis of no-carrier-added n-(4-dipropylaminobutyl)-4-[125I] iodobenzamide, a promising tracer for the detection of melanoma. J Label Compd Radiopharm. 1998;41:965–975
  14. Labarre P, Papon J, Moreau MF, Moins N, Veyre A, Madelmont JC. Evaluation in mice of some iodinated melanoma imaging agents using cryosectioning and multiwire proportional counting. Eur J Nucl Med. 1999;26:494–498
  15. Moins N, Papon J, Seguin H, Gardette D, Moreau MF, Labarre P, et al. Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents. Nucl Med Biol. 2001;28:799–808
  16. Moins N, D'Incan M, Bonafous J, Bacin J, Labarre P, Moreau MF, et al. 123I-N(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging. Eur J Nuc Med. 2002;29:1478–1484
  17. Labarre P, Papon J, Moreau MF, Moins N, Bayle M, Veyre A, et al. Melanin affinity of N-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent. Melanoma Res. 2002;12:115–121
  18. Moreau MF, Papon J, Labarre P, Moins N, Borel M, Bayle M, et al. Synthesis, in vitro binding and biodistribution in B16 melanoma bearing mice of new iodine-125 spermidine benzamides derivatives. Nucl Med Biol. 2005;32:377–384
  19. Mansard S, Papon J, Moreau MF, Miot-Noirault E, Labarre P, Bayle M, et al. Uptake in melanoma cells of [N-(2-diethylaminoethyl)-2-iodobenzamide],BZA2, an imaging agent for melanoma staging: relation to pigmentation. Nucl Med Biol. 2005;32:451–458
  20. Pham TQ, Greguric I, Liu X, Berghofer P, Ballantyne P, Chapman J, et al. Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma. J Med Chem. 2007;
  21. Pham TQ, Berghofer P, Liu X, Greguric I, Dikic B, Ballantyne P, et al. Preparation and biologic evaluation of a novel radioiodinated benzylpiperazine, 123-IMEL037, for malignant melanoma. J Nucl Med. 2007;48:1348–1356
  22. Turner JH, Rose AH, Glancy RJ, Penhale WJ. Orthotopic xenografts of human melanoma and colonic and ovarian carcinoma in sheep to evaluate radioimmunotherapy. Br J Cancer. 1998;78(4):486–494
  23. Rose AH, Ilett KF, O'Donoghue HL, Hackett LP, Penhale WJ, Manning LS, et al. Cyclosporin immununosuppression of sheep: pharmacokinetics and allograft survival. Vet Immunol Immunop. 2001;81:23–36
  24. Guerquin-Kern JL, Wu TD, Quintana C, Croisy A. Progress in analytical imaging of the cell by dynamic ion mass spectrometry (SIMS microscopy). Biochim Biophys Acta. 2005;1724:228–238
  25. Rasband WS. (1997–2007) ImageJ. http://rsb.info.nih.gov/ij/.
  26. Chehade F, Delabriolle-Vaylet C, Michelot J, Moins N, Moreau MF, Hindié E, et al. Distribution of I-BZA (N-2-diethylaminoethyl-4-iodobenzamide) in grafted melanoma and normal skin: a study by secondary ion mass spectroscopy. Cell Mol Biol. 2001;47:529–534
  27. Guerquin-Kern JL, Hillion F, Madelmont JC, Labarre P, Papon J, Croisy A. Ultra-structural cell distribution of the melanoma marker iodobenzamide: improved potentiality of SIMS imaging in life sciences. BioMedical Engineering OnLine. 2004;
  28. Chatal JF, Hoefnagel CA. Radionuclide therapy. Lancet. 1999;354:931–935
  29. Baulieu JL, Resche I, Bardies M, Faivre Chauvet A, Lecloirec J, Malhaire JP, et al. [131]-Tyr3-octreotide: clinical dosimetry and use for internal radiotherapy of metastatic paraganglioma and carcinoid tumors. Nucl Med Biol. 2000;27:809–813
  30. Kassis AI. Cancer therapy with auger electrons: are we almost there?. J Nucl Med. 2003;44(9):1479–1481

PII: S0969-8051(08)00172-8

doi: 10.1016/j.nucmedbio.2008.07.003

Nuclear Medicine and Biology
Volume 35, Issue 7 , Pages 783-791 , October 2008

Article Tools

* Image Usage & Resolution